Mastodon

ReAquatant (Powder) Instructions for Use

ATC Code

A07CA (Oral rehydrating salt preparations)

Clinical-Pharmacological Group

Oral rehydration drug

Pharmacotherapeutic Group

Antidiarrheal, intestinal anti-inflammatory/antimicrobial agents; electrolytes in combination with carbohydrates; oral salt compositions for rehydration

Pharmacological Action

Rehydrating agent. Prevents or reduces body dehydration by replenishing sodium and potassium salts, creates conditions leading to the normalization of the acid-base state.

Indications

Dehydration: diarrhea (including in children).

ICD codes

ICD-10 code Indication
A09 Other and unspecified gastroenteritis and colitis of infectious origin
E86 Volume depletion (including dehydration, hypovolemia)
K59.1 Functional diarrhea
ICD-11 code Indication
1A40.Z Infectious gastroenteritis or colitis, unspecified
5C70.Z Decrease of volume of fluid [hypovolemia], unspecified
DD91.2 Functional diarrhea
DD93.Y Other specified functional gastrointestinal disorders in infants, toddlers and school-age children
DD9Z Functional gastrointestinal disorders, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Dissolve the entire contents of one sachet in one liter of freshly boiled and cooled drinking water.

Use the prepared solution within 24 hours; discard any unused portion after this period.

Administer the solution orally in small, frequent volumes.

For rehydration, administer a minimum dose of 30 ml per kg of body weight over a period of 6 to 10 hours following the onset of diarrhea.

For outpatient maintenance therapy, administer an average dose of 60 ml per kg of body weight over a 24-hour period until diarrhea ceases.

Adjust the total volume administered according to the patient’s fluid losses, as determined by the number and volume of stools and the presence of vomiting.

For pediatric patients, calculate the dose based on body weight and administer using a spoon or bottle in small, frequent amounts.

In cases of vomiting, pause administration for 10 minutes following an episode, then resume giving the solution slowly, in small sips.

Continue administration to replace ongoing fluid losses from persistent diarrhea.

Do not exceed recommended dosages unless directed by a physician based on confirmed electrolyte needs.

Seek immediate medical attention for signs of severe dehydration or if symptoms worsen despite therapy.

Adverse Reactions

Systemic reactions risk of developing hypernatremia (increased sodium content in the blood).

Contraindications

Severe dehydration; coma (unconscious state); intestinal obstruction; severe vomiting; diarrhea caused by cholera; glucose-galactose malabsorption; hypersensitivity to the components of the combination.

Use in Pregnancy and Lactation

In recommended doses, it can be used during pregnancy and lactation.

Pediatric Use

If it is necessary to use in children, the instructions should be carefully studied.

Special Precautions

Given the composition of the drug, caution should be exercised in patients with diabetes mellitus, impaired liver or kidney function, as well as in patients on a low-salt diet (sodium and/or potassium).

In patients with diabetes mellitus, renal failure and some other chronic diseases, diarrhea can cause a significant disruption in maintaining fluid or glucose balance. Therefore, the treatment of diarrhea in such patients may require laboratory monitoring and hospitalization.

If the patient’s need for additional electrolyte administration is not confirmed by laboratory tests, the recommended doses should not be exceeded.

Severe dehydration (weight loss >10%, cessation of urination) should be treated with intravenous rehydration drugs, after which the use of the solution can be started.

In case of vomiting, wait 10 minutes after the end of the vomiting episode and give the solution to drink slowly, in small sips.

The patient should consult a doctor if the following situations occur during use:

  • Slurred speech, irritability, rapid fatigue, drowsiness, stupor occur;
  • Temperature rises above 39°C (102.2°F);
  • Bloody stools;
  • Persistent vomiting;
  • Diarrhea lasts more than 2 days;
  • Severe abdominal pain.

The use of this combination to replenish salt loss in diarrhea developing in cholera and a number of other severe intestinal infections may be insufficient.

Persons with renal failure or on a low-potassium diet should take into account that the preparation contains potassium.

Drug Interactions

The drug solution has a weakly alkaline reaction, therefore it can affect medicinal products whose absorption depends on the pH of the intestinal contents.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Finn Pharma, JSC (Russia)

Manufactured By

Pharmacor Production, LLC (Russia)

Dosage Form

Bottle OTC Icon ReAquatant Powder for oral solution: sachet 18.9 g 2, 4, 6, 10, 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Powder for oral solution white or almost white in color.

1 sachet 1 L of prepared solution
Sodium chloride 3.5 g 59.9 mmol
Potassium chloride 2.5 g 33.5 mmol
Sodium citrate dihydrate 2.9 g 9.9 mmol
Dextrose 10 g 55.5 mmol
Including
   Na+ 89.6 mmol
   K+ 33.5 mmol
   Cl– 93.4 mmol
   Citrate 9.9 mmol

18.9 g – sachets (2) – cardboard packs.
18.9 g – sachets (4) – cardboard packs.
18.9 g – sachets (6) – cardboard packs.
18.9 g – sachets (10) – cardboard packs.
18.9 g – sachets (20) – cardboard packs.
18.9 g – sachets (30) – cardboard packs.

Marketing Authorization Holder

Finn Pharma, JSC (Russia)

Manufactured By

Pharmacor Production, LLC (Russia)

Dosage Form

Bottle OTC Icon ReAquatant Optim Powder for oral solution

Dosage Form, Packaging, and Composition

Powder for oral solution

1 sachet
Sodium chloride 1.3 g
Potassium chloride 0.75 g
Sodium citrate dihydrate 1.45 g
Dextrose 6.75 g
Ionic composition per 1 L of prepared solution
   Sodium ion 75 mmol
   Chloride ion 65 mmol
   Glucose 75 mmol
   Potassium ion 20 mmol
   Citrate ion 10 mmol

Total osmolarity of the prepared solution 245 mOsm/L.

10.48 g – sachets (10 pcs.) – cardboard packs – Over-the-Counter
10.48 g – sachets (2 pcs.) – cardboard packs – Over-the-Counter
10.48 g – sachets (20 pcs.) – cardboard packs – Over-the-Counter
10.48 g – sachets (30 pcs.) – cardboard packs – Over-the-Counter
10.48 g – sachets (4 pcs.) – cardboard packs – Over-the-Counter
10.48 g – sachets (6 pcs.) – cardboard packs – Over-the-Counter

Table of Contents

→ TABLE OF CONTENTS